Cohance Lifesciences Ltd
Fri 22/05/2026,15:55:24 | NSE : COHANCE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 424.00
Previous Close
₹ 419.90
Volume
461210
Mkt Cap ( Rs. Cr)
₹16012.35
High
₹ 424.00
Low
₹ 416.60
52 Week High
₹ 1121.15
52 Week Low
₹ 266.70
Book Value Per Share
₹ 99.77
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Cohance Lifesciences Ltd
Your Vote -
Buy
63.16%
Hold
26.32%
Sell
10.53%
63.16%
19 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
418.55
530
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
530
Option Chain
Analyzes market sentiment, predicts Cohance Lifesciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Cohance Lifesciences - Copy of Newspaper Publication
-
Cohance Lifesciences - Shareholders meeting
-
Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Cohance Lifesciences - Copy of Newspaper Publication
-
Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Cohance Lifesciences - Investor Presentation
-
Cohance Lifesciences - Outcome of Board Meeting
-
Cohance Lifesciences Q4 net profit down 22.06% at Rs 34.56 cr
-
Cohance Lifesciences - Outcome Of The Board Meeting
-
Cohance Lifesciences - Board Meeting Outcome for Outcome Of The Board Meeting
-
Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Cohance Lifesciences - Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Con
-
Cohance Lifesciences - Price movement
-
Cohance Lifesciences - Clarification On Movement In Price Of Equity Shares
-
Cohance Lifesciences - Price movement
-
Cohance Lifesciences - Clarification sought from Cohance Lifesciences Ltd
-
Cohance Lifesciences - Resignation of Director/KMP/SMP
-
Cohance Lifesciences - General Updates
-
Cohance Lifesciences - Brief Profile Of Mr. Umang Vohra, Chairman And Group CEO
-
Cohance Lifesciences - Press Release
-
Cohance Lifesciences - Outcome of Board Meeting
-
Umang Vohra appointed Executive Chairman & Group CEO of Cohance Lifesciences
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Cohance Lifesciences - Board Meeting Outcome for Outcome Of Board Meeting
-
Cohance Lifesciences has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Cohance Lifesciences - Clarification With Respect To Volume Movement
-
Cohance Lifesciences - Clarification sought from Cohance Lifesciences Ltd
-
Cohance Lifesciences - Spurt in Volume
-
Cohance Lifesciences - Spurt in Volume
-
Cohance Lifesciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Cohance Lifesciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Cohance Lifesciences - Appointment
-
Cohance Lifesciences - Trading Window
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Cohance Lifesciences - Options to purchase securities
-
Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Suven Pharmaceuticals
-
Suven Pharmaceutical up on to buy stake in Hyderabad based CDMO
-
Suven Pharmaceuticals
-
Suven Pharma gets nod from Chemical & Fertilizer Ministry for acquisition.
-
Suven Pharma
-
Advent to acquire significant stake in Suven Pharma
-
Suven Pharma USFDA completes inspection of Casper Unit
-
Suven Pharmaceuticals
-
Suven Pharma to acquire Hyderabad-based formulation co Casper Pharma for Rs 155. cr
-
Suven Pharmaceuticals trades strong
-
Suven Pharmaceuticals enters into agreement with CSIR
-
Suven Pharma
-
Suven Pharmaceuticals
Key fundamentals
Evaluate the intrinsic value of Cohance Lifesciences Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 4575.35 | 2385.55 | 2094.4715 | 1818.5426 | 1616.2667 |
| Liabilities | 4575.35 | 2385.55 | 2094.4715 | 1818.5426 | 1616.2667 |
| Equity | 38.26 | 25.46 | 25.4565 | 25.4565 | 25.4565 |
| Gross Profit | 454.41 | 362.57 | 409.8999 | 583.0776 | 579.9883 |
| Net Profit | 228.71 | 271.71 | 304.8161 | 432.6025 | 558.0988 |
| Cash From Operating Activities | 389.57 | 301.03 | 370.6473 | 484.1702 | 269.8946 |
| NPM(%) | 11.26 | 24.84 | 29.73 | 32.52 | 42.27 |
| Revenue | 2030.5 | 1093.51 | 1024.9932 | 1330.0798 | 1320.2221 |
| Expenses | 1576.09 | 730.94 | 615.0933 | 747.0022 | 740.2338 |
| ROE(%) | 5.99 | 7.11 | 7.98 | 11.33 | 14.62 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 09 Sep 2022 | 5 | 500 | 0 | 491.1 |
| 09 Sep 2022 | 1 | 100 | 0 | 468.7 |
| 13 May 2022 | 1 | 100 | 0 | 586 |
| 15 Feb 2022 | 2 | 200 | 0 | 551.45 |
| 15 Feb 2022 | 1 | 100 | 0 | 538.35 |
| 13 Aug 2021 | 1 | 100 | 0 | 496.45 |
| 17 Feb 2021 | 1 | 100 | 0 | 480.15 |
Peers
Other companies within the same industry or sector that are comparable to Cohance Lifesciences Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.80 | -0.07 | 0.00 | 238.85 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 109.19 | 1.26 | 352.23 | 870.33 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.00 | 0.14 | 0.00 | 5459.84 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 771.80 | 4.77 | 0.00 | 820.74 | -363.15 | 0.00 |
Company Info
The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma. 2023 --Advent International announces the completion of the acquisition of Suven Pharma"". --Suven Pharma to manufacture anti-covid drugs Molnupiravir and 2-DG 2024 -Amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Ltd' -The company has informed that Record date for the purpose of Merger/HiveOff is 08-May-2025. 2025 -Company name has changed to Cohance Lifesciences Ltd. from Suven Pharmaceuticals Ltd..
The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma. 2023 --Advent International announces the completion of the acquisition of Suven Pharma"". --Suven Pharma to manufacture anti-covid drugs Molnupiravir and 2-DG 2024 -Amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Ltd' -The company has informed that Record date for the purpose of Merger/HiveOff is 08-May-2025. 2025 -Company name has changed to Cohance Lifesciences Ltd. from Suven Pharmaceuticals Ltd..
Read More
Parent Organisation
Cohance Lifesciences Ltd.
Founded
06/11/2018
Managing Director
Dr.V Prasada Raju
NSE Symbol
COHANCEEQ
FAQ
The current price of Cohance Lifesciences Ltd is ₹ 418.55.
The 52-week high for Cohance Lifesciences Ltd is ₹ 424.00 and the 52-week low is ₹ 416.60.
The market capitalization of Cohance Lifesciences Ltd is currently ₹ 16012.35. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Cohance Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Cohance Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Cohance Lifesciences Ltd shares.
The CEO of Cohance Lifesciences Ltd is Dr.V Prasada Raju, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
